Phospho-BCAR1 (Tyr410) Antibody

What is BCAR1 and why is the phosphorylation at Tyr410 significant?

BCAR1 (Breast cancer anti-estrogen resistance protein 1), also known as p130Cas, functions as a scaffold protein that integrates large multi-protein complexes in response to various stimuli including hormones, growth factors, and integrin engagement. The protein contains a unique structure with a Src homology (SH-3) domain followed by multiple YXXP motifs and a proline-rich region .

Phosphorylation at Tyr410 is particularly significant because:

• It represents one of multiple tyrosine phosphorylation sites (others include residues 12, 128, 165, 192, etc.)

• It serves as an activation marker for BCAR1 signaling

• It creates binding sites for recruitment of downstream signaling proteins like Crk and Nck adaptor proteins

• It's implicated in cell migration, adhesion, and cancer progression pathways

The physiological functions of phosphorylated BCAR1 include cardiovascular development, actin filament assembly, and Src-induced cell transformation .

How is BCAR1 connected to cancer pathogenesis?

BCAR1 has been extensively studied in cancer research due to its involvement in critical cellular processes:

• Breast cancer: Overexpression confers antiestrogen resistance on breast cancer cells, as indicated by its name (Breast Cancer Anti-estrogen Resistance protein 1)

• Non-small-cell lung cancer (NSCLC): Higher BCAR1 levels are strongly associated with poorly differentiated NSCLC and predict poorer prognosis

• Cell migration and invasion: BCAR1 plays a central coordinating role in tyrosine kinase-based signaling related to cell adhesion and migration, key processes in cancer metastasis

• Signaling pathway integration: It acts as a docking platform for multiple signaling proteins, integrating signals from various pathways including Src family kinases

Research has demonstrated that BCAR1 knockdown in A549 lung adenocarcinoma cells caused cell growth arrest, cell migration inhibition, and cell cycle arrest, supporting its role in carcinogenesis .

What are the optimal methods for detecting phosphorylated BCAR1 (Tyr410) in different sample types?

Detection of phosphorylated BCAR1 (Tyr410) can be accomplished through several techniques, each with specific advantages depending on your experimental design:

Western Blotting (Immunoblotting):

• Recommended dilution: 1:500-1:2000

• Sample preparation: Use pervanadate-treated cells as positive controls

• Buffer considerations: PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 for antibody storage

• Expected molecular weight: 130 kDa

Cell-Based ELISA:

• Advantage: Allows for lysate-free, high-throughput screening

• Format: Indirect ELISA where phospho-BCAR1 (Tyr410) is captured by specific antibodies, followed by dye-conjugated secondary antibodies

• Controls: Include antibodies against non-phosphorylated BCAR1 and GAPDH for normalization

• Detection: Fluorometric measurement of relative fluorescence units (RFU)

Immunohistochemistry (IHC):

• Recommended dilution: 1:100-1:500 for IHC-P

• Cellular localization: Primarily cytoplasmic and membrane-associated

• Positive tissues: NSCLC tissues show stronger staining compared to adjacent normal tissues

Immunocytochemistry (ICC)/Immunofluorescence (IF):

• Allows visualization of subcellular localization

• Can be used to monitor changes in phosphorylation status following stimulation

How can I validate the specificity of a Phospho-BCAR1 (Tyr410) antibody?

Validating antibody specificity is crucial for reliable results. For Phospho-BCAR1 (Tyr410) antibodies, consider these validation approaches:

Phosphatase Treatment Control:

• Split your sample and treat one portion with lambda phosphatase

• The phospho-specific signal should disappear in the phosphatase-treated sample while total BCAR1 remains detectable

Stimulation Experiments:

• Use known activators of BCAR1 phosphorylation (e.g., pervanadate, integrin engagement, growth factors)

• Compare treated versus untreated samples to demonstrate increased phospho-signal

Knockout/Knockdown Validation:

• Use BCAR1 knockdown cells (siRNA or CRISPR) as negative controls

• The specific band should be absent or significantly reduced in knockdown samples

Peptide Competition:

• Pre-incubate the antibody with the immunizing phosphopeptide

• The specific signal should be blocked when the antibody is neutralized by the peptide

Parallel Detection:

• Compare with other validated phospho-BCAR1 antibodies

• Use total BCAR1 antibody on the same samples to verify protein presence

How does phosphorylation at Tyr410 differ functionally from other BCAR1 phosphorylation sites?

BCAR1 contains multiple phosphorylation sites with distinct functional implications:

Research findings on Tyr410 specificity:

• While phospho-BCAR1(Tyr410) was detected in 29 of 60 NSCLC samples by immunoblotting, there was no significant difference between tumor and adjacent normal tissues (25.3±11.2 vs 27.8±15.2, P = 0.476)

• This contrasts with total BCAR1 expression, which was significantly higher in NSCLC compared to normal adjacent tissue (48.2±24.7 vs 11.0±9.8, P<0.001)

• Intriguingly, adjacent normal tissues showed higher levels of phospho-BCAR1 than of total BCAR1 proteins, suggesting possible differential regulation

These observations indicate that Tyr410 phosphorylation may have tissue-specific roles distinct from other phosphorylation sites, and that the relationship between total BCAR1 and its phosphorylated forms is complex.

What signaling pathways are specifically activated downstream of BCAR1 Tyr410 phosphorylation?

Phosphorylation of BCAR1 at Tyr410 initiates several signaling cascades:

Src/BCAR1/Crk/DOCK180/Rac Pathway:

• Phosphorylated BCAR1 recruits Crk adaptor proteins

• Crk binds DOCK180, activating Rac GTPase

• Results in membrane ruffling, lamellipodia formation, and cell migration

MAPK Pathway Activation:

• Strong correlation observed between BCAR1 overexpression and p38 MAPK activation in NSCLC tissues (correlation coefficient = 0.811, p<0.001)

• BCAR1 knockdown causes reduction of phospho-p38 abundance in A549 cells

• Suggests a BCAR1/p38 MAPK axis in cancer progression

PI3K/AKT Signaling:

• BCAR1 phosphorylation can lead to AKT activation

• Promotes cell survival and antiapoptotic signals

• Contributes to therapeutic resistance

Cell Cycle Regulation:

• BCAR1 levels influence cell cycle progression

• BCAR1 knockdown causes cell cycle arrest in A549 cells

• May involve cyclin D1 regulation

Understanding these pathways is crucial for developing targeted therapeutic approaches in cancers with BCAR1 overexpression or hyperactivation.

How can I address inconsistent phospho-BCAR1 (Tyr410) detection in my experiments?

Inconsistent detection of phospho-BCAR1 (Tyr410) can arise from multiple factors:

Sample Preparation Issues:

• Phosphorylation is labile: Use phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride) in all buffers

• Quick processing: Minimize time between sample collection and processing

• Preserve phosphorylation: Use ice-cold buffers and maintain samples at 4°C

• Consider using pervanadate treatment as a positive control

Technical Considerations:

• Antibody dilution: Titrate the antibody to find optimal concentration (1:500-1:2000 for WB)

• Blocking conditions: Test different blocking agents (BSA vs. milk) as milk contains phosphatases

• Membrane selection: PVDF membranes may work better than nitrocellulose for phospho-proteins

• Storage conditions: Store antibodies at -20°C with glycerol to prevent freeze/thaw damage

Biological Variables:

• Phosphorylation is dynamic: Standardize conditions and timepoints

• Cell confluence effects: Maintain consistent cell density

• Serum components: Serum starvation before stimulation may reduce background

Control Experiments:

• Always include total BCAR1 antibody detection in parallel

• Use GAPDH or other housekeeping proteins for normalization

• Consider including cellular treatment known to induce BCAR1 phosphorylation

How should I interpret contradictory findings between phospho-BCAR1 (Tyr410) levels and total BCAR1 expression?

Research has revealed complex relationships between phospho-BCAR1 (Tyr410) and total BCAR1:

Interpretation Approaches:

How can Phospho-BCAR1 (Tyr410) detection be utilized in precision medicine approaches?

Emerging applications of phospho-BCAR1 (Tyr410) detection in precision medicine:

Potential as a Biomarker:

• While total BCAR1 overexpression correlated with poor prognosis in NSCLC, phospho-BCAR1(Tyr410) did not correlate with clinical-pathological characteristics

• This suggests phosphorylation at specific sites may need to be evaluated in combination with total protein levels

Therapeutic Target Identification:

• Monitoring phospho-BCAR1 can help identify patients likely to respond to specific targeted therapies

• BCAR1 is known to promote antiestrogen resistance, suggesting potential for combination therapy strategies

Response Monitoring:

• Cell-based ELISA kits allow for screening the effects of various treatments, inhibitors (siRNA or chemicals), or activators on BCAR1 phosphorylation

• This can be valuable for measuring drug efficacy in real-time

Pathway-Specific Targeting:

• The correlation between BCAR1 overexpression and p38 MAPK activation suggests targeting both pathways simultaneously might be effective

• Src inhibitors like AZD0530 may inhibit BCAR1 phosphorylation, affecting cell migration and invasion

What are the current technical limitations in studying BCAR1 phosphorylation dynamics across multiple sites?

Current limitations and challenges in multi-site phosphorylation analysis:

Temporal Dynamics Challenges:

• Different phosphorylation sites may have distinct kinetics

• Current methods often provide static snapshots rather than dynamic information

• Limited ability to track sequential phosphorylation events

Technical Limitations:

• Antibody cross-reactivity between similar phosphorylation motifs

• Difficulty in generating antibodies against all relevant phosphorylation sites

• Mass spectrometry requires specialized equipment and expertise

Functional Interpretation Challenges:

• Multiple phosphorylation sites create complex combinatorial patterns

• Difficulty determining which combinations are functionally significant

• Limited understanding of how different phosphorylation sites interact

Cellular Heterogeneity:

• Phosphorylation patterns may differ between cell subpopulations

• Bulk analysis methods may miss important differences in rare cell types

• Single-cell phospho-protein analysis techniques are still emerging

Future Directions:

• Development of multiplexed phospho-specific antibody arrays

• Advanced mass spectrometry techniques for comprehensive phosphorylation profiling

• Live-cell imaging with phosphorylation-specific biosensors

• Computational models to predict functional consequences of multi-site phosphorylation

By addressing these limitations, researchers will gain deeper insights into the complex regulation of BCAR1 signaling and its role in normal physiology and disease.